Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy
Identifieur interne : 007F32 ( Main/Merge ); précédent : 007F31; suivant : 007F33Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy
Auteurs : Rascol [France] ; Kasia Sieradzan [Royaume-Uni] ; Hélène Peyro-Saint-Paul [France] ; Claire Thalamas [France] ; Christine Brefel-Courbon [France] ; Jean Michel Senard [France] ; Philippe Ladure [France] ; Jean Louis Montastruc [France] ; Andrew Lees (neurologue) [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1998-07.
English descriptors
- KwdEn :
- Adrenergic alpha-Antagonists (adverse effects), Adrenergic alpha-Antagonists (therapeutic use), Adult, Aged, Alpha‐2 antagonist, Benzofurans (adverse effects), Benzofurans (therapeutic use), Clinical trial, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Efaroxan, Female, Humans, Imidazoles (adverse effects), Imidazoles (therapeutic use), Male, Middle Aged, Neurologic Examination (drug effects), Progressive supranuclear palsy, Prospective Studies, Supranuclear Palsy, Progressive (diagnosis), Supranuclear Palsy, Progressive (drug therapy), Supranuclear Palsy, Progressive (physiopathology), Treatment Outcome.
- MESH :
- chemical , adverse effects : Adrenergic alpha-Antagonists, Benzofurans, Imidazoles.
- chemical , therapeutic use : Adrenergic alpha-Antagonists, Benzofurans, Imidazoles.
- diagnosis : Supranuclear Palsy, Progressive.
- drug effects : Neurologic Examination.
- drug therapy : Supranuclear Palsy, Progressive.
- physiopathology : Supranuclear Palsy, Progressive.
- Adult, Aged, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome.
Abstract
We have tested, in a prospective randomized, double‐blind, placebo‐controlled, crossover, 12‐week study, the effects of 2 mg efaroxan, a potent alpha‐2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant change on any motor assessment criteria. The present data do not confirm the assumption that the blockade of alpha‐2 receptors might be a useful pharmacologic strategy to improve patients with progressive supranuclear palsy.
Url:
DOI: 10.1002/mds.870130411
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003318
- to stream Istex, to step Curation: 003318
- to stream Istex, to step Checkpoint: 003755
- to stream PubMed, to step Corpus: 004377
- to stream PubMed, to step Curation: 004377
- to stream PubMed, to step Checkpoint: 004449
- to stream Ncbi, to step Merge: 005006
- to stream Ncbi, to step Curation: 005006
- to stream Ncbi, to step Checkpoint: 005006
Links to Exploration step
ISTEX:15F0DC720320C512DF4B0A780CCBB502A45139EELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy</title><author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name></author><author><name sortKey="Sieradzan, Kasia" sort="Sieradzan, Kasia" uniqKey="Sieradzan K" first="Kasia" last="Sieradzan">Kasia Sieradzan</name></author><author><name sortKey="Peyro Aint Aul, Helene" sort="Peyro Aint Aul, Helene" uniqKey="Peyro Aint Aul H" first="Hélène" last="Peyro-Saint-Paul">Hélène Peyro-Saint-Paul</name></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean Michel" last="Senard">Jean Michel Senard</name></author><author><name sortKey="Ladure, Philippe" sort="Ladure, Philippe" uniqKey="Ladure P" first="Philippe" last="Ladure">Philippe Ladure</name></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name><affiliation><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:15F0DC720320C512DF4B0A780CCBB502A45139EE</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130411</idno><idno type="url">https://api.istex.fr/document/15F0DC720320C512DF4B0A780CCBB502A45139EE/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003318</idno><idno type="wicri:Area/Istex/Curation">003318</idno><idno type="wicri:Area/Istex/Checkpoint">003755</idno><idno type="wicri:doubleKey">0885-3185:1998:Rascol:efaroxan:an:alpha</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9686773</idno><idno type="wicri:Area/PubMed/Corpus">004377</idno><idno type="wicri:Area/PubMed/Curation">004377</idno><idno type="wicri:Area/PubMed/Checkpoint">004449</idno><idno type="wicri:Area/Ncbi/Merge">005006</idno><idno type="wicri:Area/Ncbi/Curation">005006</idno><idno type="wicri:Area/Ncbi/Checkpoint">005006</idno><idno type="wicri:doubleKey">0885-3185:1998:Rascol O:efaroxan:an:alpha</idno><idno type="wicri:Area/Main/Merge">007F32</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy</title><author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Sieradzan, Kasia" sort="Sieradzan, Kasia" uniqKey="Sieradzan K" first="Kasia" last="Sieradzan">Kasia Sieradzan</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Manchester Royal Infirmary</wicri:regionArea><wicri:noRegion>Manchester Royal Infirmary</wicri:noRegion></affiliation></author><author><name sortKey="Peyro Aint Aul, Helene" sort="Peyro Aint Aul, Helene" uniqKey="Peyro Aint Aul H" first="Hélène" last="Peyro-Saint-Paul">Hélène Peyro-Saint-Paul</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche P. Fabre, Boulogne</wicri:regionArea><wicri:noRegion>Boulogne</wicri:noRegion><wicri:noRegion>Boulogne</wicri:noRegion></affiliation></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean Michel" last="Senard">Jean Michel Senard</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Ladure, Philippe" sort="Ladure, Philippe" uniqKey="Ladure P" first="Philippe" last="Ladure">Philippe Ladure</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche P. Fabre, Boulogne</wicri:regionArea><wicri:noRegion>Boulogne</wicri:noRegion><wicri:noRegion>Boulogne</wicri:noRegion></affiliation></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-07">1998-07</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="673">673</biblScope><biblScope unit="page" to="676">676</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">15F0DC720320C512DF4B0A780CCBB502A45139EE</idno><idno type="DOI">10.1002/mds.870130411</idno><idno type="ArticleID">MDS870130411</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic alpha-Antagonists (adverse effects)</term><term>Adrenergic alpha-Antagonists (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Alpha‐2 antagonist</term><term>Benzofurans (adverse effects)</term><term>Benzofurans (therapeutic use)</term><term>Clinical trial</term><term>Cross-Over Studies</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Efaroxan</term><term>Female</term><term>Humans</term><term>Imidazoles (adverse effects)</term><term>Imidazoles (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Progressive supranuclear palsy</term><term>Prospective Studies</term><term>Supranuclear Palsy, Progressive (diagnosis)</term><term>Supranuclear Palsy, Progressive (drug therapy)</term><term>Supranuclear Palsy, Progressive (physiopathology)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adrenergic alpha-Antagonists</term><term>Benzofurans</term><term>Imidazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic alpha-Antagonists</term><term>Benzofurans</term><term>Imidazoles</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Cross-Over Studies</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have tested, in a prospective randomized, double‐blind, placebo‐controlled, crossover, 12‐week study, the effects of 2 mg efaroxan, a potent alpha‐2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant change on any motor assessment criteria. The present data do not confirm the assumption that the blockade of alpha‐2 receptors might be a useful pharmacologic strategy to improve patients with progressive supranuclear palsy.</div></front></TEI><double doi="10.1002/mds.870130411"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy</title><author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name></author><author><name sortKey="Sieradzan, Kasia" sort="Sieradzan, Kasia" uniqKey="Sieradzan K" first="Kasia" last="Sieradzan">Kasia Sieradzan</name></author><author><name sortKey="Peyro Aint Aul, Helene" sort="Peyro Aint Aul, Helene" uniqKey="Peyro Aint Aul H" first="Hélène" last="Peyro-Saint-Paul">Hélène Peyro-Saint-Paul</name></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean Michel" last="Senard">Jean Michel Senard</name></author><author><name sortKey="Ladure, Philippe" sort="Ladure, Philippe" uniqKey="Ladure P" first="Philippe" last="Ladure">Philippe Ladure</name></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name><affiliation><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:15F0DC720320C512DF4B0A780CCBB502A45139EE</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130411</idno><idno type="url">https://api.istex.fr/document/15F0DC720320C512DF4B0A780CCBB502A45139EE/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003318</idno><idno type="wicri:Area/Istex/Curation">003318</idno><idno type="wicri:Area/Istex/Checkpoint">003755</idno><idno type="wicri:doubleKey">0885-3185:1998:Rascol:efaroxan:an:alpha</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy</title><author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Sieradzan, Kasia" sort="Sieradzan, Kasia" uniqKey="Sieradzan K" first="Kasia" last="Sieradzan">Kasia Sieradzan</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Manchester Royal Infirmary</wicri:regionArea><wicri:noRegion>Manchester Royal Infirmary</wicri:noRegion></affiliation></author><author><name sortKey="Peyro Aint Aul, Helene" sort="Peyro Aint Aul, Helene" uniqKey="Peyro Aint Aul H" first="Hélène" last="Peyro-Saint-Paul">Hélène Peyro-Saint-Paul</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche P. Fabre, Boulogne</wicri:regionArea><wicri:noRegion>Boulogne</wicri:noRegion><wicri:noRegion>Boulogne</wicri:noRegion></affiliation></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean Michel" last="Senard">Jean Michel Senard</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Ladure, Philippe" sort="Ladure, Philippe" uniqKey="Ladure P" first="Philippe" last="Ladure">Philippe Ladure</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche P. Fabre, Boulogne</wicri:regionArea><wicri:noRegion>Boulogne</wicri:noRegion><wicri:noRegion>Boulogne</wicri:noRegion></affiliation></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-07">1998-07</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="673">673</biblScope><biblScope unit="page" to="676">676</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">15F0DC720320C512DF4B0A780CCBB502A45139EE</idno><idno type="DOI">10.1002/mds.870130411</idno><idno type="ArticleID">MDS870130411</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alpha‐2 antagonist</term><term>Clinical trial</term><term>Efaroxan</term><term>Progressive supranuclear palsy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have tested, in a prospective randomized, double‐blind, placebo‐controlled, crossover, 12‐week study, the effects of 2 mg efaroxan, a potent alpha‐2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant change on any motor assessment criteria. The present data do not confirm the assumption that the blockade of alpha‐2 receptors might be a useful pharmacologic strategy to improve patients with progressive supranuclear palsy.</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacology, University Hospital, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Sieradzan, K" sort="Sieradzan, K" uniqKey="Sieradzan K" first="K" last="Sieradzan">K. Sieradzan</name></author><author><name sortKey="Peyro Saint Paul, H" sort="Peyro Saint Paul, H" uniqKey="Peyro Saint Paul H" first="H" last="Peyro-Saint-Paul">H. Peyro-Saint-Paul</name></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C" last="Thalamas">C. Thalamas</name></author><author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C" last="Brefel-Courbon">C. Brefel-Courbon</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Ladure, P" sort="Ladure, P" uniqKey="Ladure P" first="P" last="Ladure">P. Ladure</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author><author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A" last="Lees">A. Lees</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9686773</idno><idno type="pmid">9686773</idno><idno type="doi">10.1002/mds.870130411</idno><idno type="wicri:Area/PubMed/Corpus">004377</idno><idno type="wicri:Area/PubMed/Curation">004377</idno><idno type="wicri:Area/PubMed/Checkpoint">004449</idno><idno type="wicri:Area/Ncbi/Merge">005006</idno><idno type="wicri:Area/Ncbi/Curation">005006</idno><idno type="wicri:Area/Ncbi/Checkpoint">005006</idno><idno type="wicri:doubleKey">0885-3185:1998:Rascol O:efaroxan:an:alpha</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacology, University Hospital, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Sieradzan, K" sort="Sieradzan, K" uniqKey="Sieradzan K" first="K" last="Sieradzan">K. Sieradzan</name></author><author><name sortKey="Peyro Saint Paul, H" sort="Peyro Saint Paul, H" uniqKey="Peyro Saint Paul H" first="H" last="Peyro-Saint-Paul">H. Peyro-Saint-Paul</name></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C" last="Thalamas">C. Thalamas</name></author><author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C" last="Brefel-Courbon">C. Brefel-Courbon</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Ladure, P" sort="Ladure, P" uniqKey="Ladure P" first="P" last="Ladure">P. Ladure</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author><author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A" last="Lees">A. Lees</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic alpha-Antagonists (adverse effects)</term><term>Adrenergic alpha-Antagonists (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Benzofurans (adverse effects)</term><term>Benzofurans (therapeutic use)</term><term>Cross-Over Studies</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Imidazoles (adverse effects)</term><term>Imidazoles (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Prospective Studies</term><term>Supranuclear Palsy, Progressive (diagnosis)</term><term>Supranuclear Palsy, Progressive (drug therapy)</term><term>Supranuclear Palsy, Progressive (physiopathology)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adrenergic alpha-Antagonists</term><term>Benzofurans</term><term>Imidazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic alpha-Antagonists</term><term>Benzofurans</term><term>Imidazoles</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Cross-Over Studies</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have tested, in a prospective randomized, double-blind, placebo-controlled, crossover, 12-week study, the effects of 2 mg efaroxan, a potent alpha-2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant change on any motor assessment criteria. The present data do not confirm the assumption that the blockade of alpha-2 receptors might be a useful pharmacologic strategy to improve patients with progressive supranuclear palsy.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007F32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007F32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:15F0DC720320C512DF4B0A780CCBB502A45139EE
|texte= Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy
}}
| This area was generated with Dilib version V0.6.23. |  |